CA 125 Test Market size was over USD 1.2 billion in 2024 and is estimated to reach USD 1.9 billion by the end of 2037, expanding at a CAGR of 4.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of CA 125 test is assessed at USD 1.2 billion.
The rising prevalence of ovarian cancer across the world is the major growth factor in the CA 125 test market. According to the 2022 estimation of the Globocan, the annual OC fatalities are expected to reach 350956, increasing by 70% from 2022. The projection further states, that the number of diagnosed OC patients worldwide is estimated to be 503,448 with a 55% increment. The reliance and accuracy of CA-125 serum as a tumor marker are significantly preferred and adopted for observing the treatment progress and introducing new therapeutic discoveries. This test is also utilized by researchers for new drug developments due to its high precision and specificity.
The growing number of new and death cases is further concerning regional authorities and is forcing them to regulate policies and take initiatives to control the outrage. They are continuously promoting the importance of regular check-ups and preventive healthcare measures for early detection. Thus, women with the potential threat of having cancer are opting for routine screenings, cultivating investments in the CA 125 test market. Further studies are being conducted to advance the performance of these tests by combining different biomarkers with this antigen. For instance, in April 2024, a research paper was published by ACS Publications, introducing a more bio-based, fast, and affordable solution, organohydrogels (ONOHs) for CA-125 serum testing.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.1% |
|
Base Year Market Size (2024) |
USD 1.2 billion |
|
Forecast Year Market Size (2037) |
USD 1.9 billion |
|
Regional Scope |
|
End user (Hospital & Clinic, Diagnostic Center)
In terms of end user, CA 125 test market diagnostic segment is poised to capture over 68.4% revenue share by 2037. This group of healthcare providers is generating remarkable revenue from this sector due to their wide network of diagnostic expertise and adequate laboratories. According to a report published in March 2023, the global diagnostic testing industry was valued at USD 166 billion in 2021. It was further expected to reach USD 349 billion by 2030. They are fully equipped with essential tools for specific tests such as CA 125, making them a preferable option for undergoing patients. Their direct interaction with consumers also helps them to offer tailored and budget-friendly diagnostic services, influencing patients to invest more.
Indication (Cancer, Uterine Fibroids, Endometriosis, Liver Disease)
Based on indication, the CA 125 test market is projected to witness significant growth in the cancer segment by the end of 2037. The growing prevalence of cancers related to the ovary, endometrial, fallopian tube, breast, and other feedstocks in this sector. In addition, cancers with greater mortality rates are specifically increasing the demand for such monitoring tests. According to a study report, published in May 2024, ovarian cancer has the highest fatality rate with a survival rate of merely 50.8% in 5-year tenure. It further states, that the survival rate of early-stage OC patients has been studied to be around 92% when the same is less than 29% for patients with advanced stages. This exclaims the need for early diagnosis, surging demand in this sector.
Our in-depth analysis of the global CA 125 test market includes the following segments:
|
End user |
|
|
Indication |
|
|
Device & Accessory |
|
North America Market Analysis
North America in CA 125 test market is set to capture over 47.3% revenue share by 2037. Well-developed economies such as the U.S. and Canada are known for their highly equipped and efficient medical facilities and services. In addition, the regional R&D efforts to regulate more accurate and faster testing results are further accumulating growth in this sector. For instance, in September 2024, a study report was published by researchers at Johns Hopkins Kimmel Cancer Center, unveiling the possibilities of integrating AI into blood tests. The study used an AI-powered analysis of DNA and protein biomarkers for the early detection of OC, making tests more accessible and affordable with high detection capabilities.
Healthcare advancements are one of the major driving factors in the U.S. when the incidence rate of related cancers such as OC is increasing. According to data released by the Centers for Disease Control and Prevention, in June 2024, the country registered 20,032 new cases of ovarian cancer in 2021. The report further revealed that around 10 new cases of OC were encountered for every 100,000 women in this country. This escalates the implementation of effective and precise tests, increasing demand in the CA 125 test market.
Canada is following in the footsteps of its regional assessments and initiatives to make progress in the CA 125 test market. The country is closely working with many R&D organizations to leverage the speed of treatment discoveries and precise diagnosis. For instance, in 2019, the government of Canada funded USD 10 million to Ovarian Cancer Canada to empower its 5-year timeline of OC research initiatives. These investments work as a financial cushion for the developers in this field to introduce innovative solutions, improving test outcomes.
APAC Market Statistics
The Asia Pacific landscape is evolving with the financial and regulatory progress of developing economies such as Japan, China, and India. The trend of investing in R&D for medical discoveries notably encourages pharma companies to innovate new molecular hybrids to enhance test accuracy. They are also exploring ways to engage this biomarker to detect a wide range of cancers. For instance, in January 2023, a team of researchers from some of the regional institutes conducted a study regarding the diagnostic capabilities of CA-125 in metastatic colorectal cancer. The results identified this antigen’s potential as a predictive and prognostic factor in later-line treatment of patients with mCRC.
India is utilizing its strong emphasis on the pharma industry to gain traction in the CA 125 test market. Besides, the wide spreading network of diagnostic centers across the country is garnering great business opportunities for the service providers and participants. According to a NABL report published in February 2024, the number of accredited medical laboratories in India reached 2150 in the same year, among which 24 were ISO-certified cancer labs. This is evidence of the scope of new developments and investments in this sector.
China is fostering resources and supply channels to reduce its growing burden of ovarian cancer. According to the NLM article, released in February 2023, the country reported to have 196,000 incident, 45,000 new, and 29,000 death cases for OC in 2019. The report further exclaimed the increment of 105.98%, 79.19%, 58.93%, 47.88%, 91.78%, and 46.81% in the ASPR, ASIR, ASMR, ASDR, and the ASRs of YLDs and YLLs of OC. The technology-driven country is now heavily contributing to the growth of its domestic CA 125 test market to control cancer outrage.
The dynamics of the CA 125 test market are shifting towards creating hybrid biomarkers by combining the designated antigen with new bio-based solutions for more precise analysis. Global leaders are focusing on investing in more R&D projects to leverage their product lines to captivate the top positions in this field. For instance, in June 2022, Roche Diagnostics launched an advanced tissue staining platform, ULTRA PLUS to enable quick and accurate test results for cancer. The new system is capable of offering testing efficiency and environmentally sustainable features to empower pathologists by providing high-quality, time-critical results to doctors and patients. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?